HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (66) Citing Articles via Google Scholar Google Scholar Articles by Hermiller, J. B. Search for Related Content PubMed PubMed Citation Articles by Hermiller, J. B.

Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus

The TAXUS-IV trial

James B. Hermiller, MD, FACC^_*,1, Albert Raizner, MD, FACC, Louis Cannon, MD, FACC, Paul A. Gurbel, MD, FACC, Michael A. Kutcher, MD, FACC^||, S. Chiu Wong, MD, FACC^¶, Mary E. Russell, MD^#,2, Stephen G. Ellis, MD, FACC^_**,1, Roxana Mehran, MD, FACC, Gregg W. Stone, MD, FACC^,1,_* TAXUS-IV Investigators

^_* St. Vincent’s Hospital, Indianapolis, Indiana
Cardiac Cath Lab Research Center, Houston, Texas
St. Mary’s Medical Center, Saginaw, Michigan
Sinai Hospital of Baltimore, Baltimore, Maryland
^|| Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
^¶ New York Presbyterian Hospital, New York, New York
^# Boston Scientific Corp., Natick, Massachusetts
^_** Cleveland Clinic Foundation, Cleveland, Ohio
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York

View larger version (32K): [in a new window]   Figure 1 One-year clinical outcomes among patients randomized to the paclitaxel-eluting TAXUS stent versus a control EXPRESS stent, stratified by diabetic status and treatment type. (Upper left graph) Composite major adverse cardiac events. (Upper right graph) Target vessel failure. (Lower left graph) Target vessel revascularization. (Lower right graph) Target lesion revascularization.

View larger version (22K): [in a new window]   Figure 2 Nine-month rates of binary restenosis among patients randomized to the paclitaxel-eluting TAXUS stent versus a control EXPRESS stent, stratified by diabetic status and treatment type. (Left) In-stent restenosis. (Right) Analysis segment restenosis. Black bars = control; open bars = TAXUS.